Submit an Abstract for ACoP11


Call for Abstracts is now open!

Deadline - 15 May 11:59 PM PDT
(Those selected will be notified between July 7 – July 10)

The abstract submission deadline has been extended. Authors of accepted abstracts (notifications to be sent July 7 – July 10) can withdraw their submission if they are unable to register for ACoP11 due to the current COVID-19 pandemic.

We are pleased to announce that abstract submission to ACoP11 is now open through April 15th! The planning committee would like to invite you to submit your work and be part of the exciting science at the conference. Please see below to find guidelines and further details for submitting your abstract.

Three Quality Abstract Awards and three Trainee Abstract Awards will be selected from submitted abstracts, and the awardees will have the opportunity to orally present their works at the main conference. In addition to those, there are four awards from ISoP special interest groups (SIGs). No separate abstract is needed for the four SIG awards and the winners will present short podium presentations during the official SIG gatherings at ACoP11.

  • The Quantitative Systems Pharmacology (QSP) SIG of ISoP will provide one QSP SIG Student Award. Any current student who submits an abstract to ACoP11 is eligible for the award.
  • The Statistics and Pharmacometrics (SxP) SIG of ISoP will provide one SxP SIG Student Award. Any current student who submits an abstract to ACoP11 is eligible for the award.
  • The Clinical Pharmacometrics SIG of ISoP will provide one Clinical Pharmacometrics SIG TraineeAward. Any current student or post-doc who submits an abstract to ACoP11 is eligible for the award.
  • The Mathematical and Computational Sciences (MCS) SIG of ISoP will proivde one MCS SIG Poster Award. Anyone who submits an abstract to ACoP11 is eligible for the award.
Poster sessions will be held on every day of the conference including the full day pre-conference, entitled "The Rising Role of Modeling in Oncology - From Translation to Confirmation" on Sunday October 4, 2020 and the main conference. If you are planning to attend the pre-conference and your work is related to the theme of the pre-conference, we encourage you to consider presenting your poster during both the pre-conference and main conference poster sessions. In addition, MCS SIG will offer a poster walk session at the main  conference, which will recognize the thought-provoking accomplishments in MCS.

For further information about the SIG awards, feel free to contact QSP SIG Vice Chair Benjamin Ribba (benjamin.ribbaATrocheDOTcom), the Clinical Pharmacometrics SIG Leadership Team ([email protected]), SxP SIG Chair France Mentre ([email protected]) or MCS SIG Chair Gilbert Koch ([email protected]).

Please reach out to us at [email protected] if you have any questions. Thank you in advance for supporting ACoP, and we look forward to seeing you in Aurora, Colorado!

Kenta Yoshida, ACoP11  Abstracts Committee Chair

On Behalf of the ACoP11 Planning Committee

 Access submission form here

Submit an Abstract for ACoP11


Abstract Considerations

All submitted abstracts will be peer reviewed. Abstracts will be reviewed on the basis of:

Relevance: Pharmacometrics has been defined as: “the science of interpreting and describing pharmacology in a quantitative fashion”, or “the science of developing and applying mathematical and statistical methods to characterize, understand and predict a drug’s pharmacokinetic, pharmacodynamic and biomarker-outcomes behavior” (Ette and Williams, 2007).

Scientific content: Abstracts are expected to be scientific in nature and contain enough information to allow for scientific review. Abstracts without results will be rejected. (Are the methods described in sufficient detail? Does the abstract contain enough concrete evidence or results to support its conclusions? Are the results, either experimental or from computer simulation, quantitatively stated, either in table or graphical format? Alternatively, for abstracts describing a process, method or software, is the algorithm well described, has it been evaluated and are results presented? If the results are preliminary, are they characterized as such? Is the abstract purely or excessively commercial or promotional in nature?)

Background: An appropriate level of background information should be provided to allow audience and reviewers to assess the scientific impact of the results or methodologies contained in the abstract (Is enough background provided for the reader to understand the abstract goal? Is the literature reviewed at least to some extent and in an unbiased manner? Are citations provided?)

Innovation: Except for ENCORE presentations*, abstracts are expected to contain novel and significant information by some scientific criterion (Are the results methodologically innovative or otherwise significant? Do they shed light on certain aspects of pharmacotherapy for a particular disease? Is the methodology novel? If the methodology is not novel, is the application (to a particular problem or disease area) original? For an ENCORE submission, is the content particularly relevant to the discipline of pharmacometrics and the expected meeting audience?)

Style: abstracts should be concisely and clearly written, including structure, language, and overall exposition (Is the abstract main goal sufficiently clear? Are the results well summarized? Are there imprecision of language or errors of syntax and/or grammar? Are measurement units reported?)

*The conference may accept a limited number of selected ENCORE presentations. Their content should be particularly relevant to the discipline of pharmacometrics and the expected meeting audience. For ENCORE presentations, submitters should disclose the previous presentation in the body of the abstract and on the poster using the following suggested format: “The results in this abstract have been previously presented in part at [conference name, venue and date] and published in the conference proceedings as abstract [number]”.

Abstracts that do not comply with the guidelines may be rejected so please take the time to conform your submission.

Abstract Guidance

Authors must adhere to a standardized format to allow for publishing. Abstracts must be uploaded as a single word document (including all elements below and any tables or figures) using Times New Roman font size 10. The word document should be named according to the following format: "". If submitting more than one abstract, please indicate the number in the file name as well, e.g. Doe_Jane1.doc and Doe_Jane2.doc. The general format of abstracts follows that of most major scientific meetings, and is described below:

Title: Abstract Title

Authors: List of all Authors

Institutions: Affiliations for listed Authors

Objectives: A brief description of the objectives/hypothesis of the work described

Methods: A brief description of the methods used to reach the stated objectives, or to test the hypothesis.

Results: A description of the results obtained

Conclusions: Conclusions that can be reached for the stated objectives and hypotheses.

References: References used to execute the work.

The maximum word count for abstract body is 450 words, including References, but excluding Title, Authors, and Affiliations. The attached word file may contain either one figure (inserted as a single image in JPEG or TIFF format with ≥ 300 dpi) or table which must include a title. Abstracts that do not adhere to the guidelines, including word limit and Figure/Table limit or format, will not be reviewed by the Abstract Committee, so please take the time to conform your submission.

An example abstract is provided here


Questions regarding the ACoP11 Abstracts can be directed to the ACoP11 Abstracts Committee Chair, Kenta Yoshida [email protected]



PS - Abstract Copyright - The authors own the copyright of the abstract(s) submitted and accepted for ACoP meeting (starting 2019 onwards). ISoP/ACoP publishes the accepted abstracts on its website to allow their work to be cited appropriately (ISSN – 2688-3953). We request that the authors reference their work as mentioned on the site.   The same applies for the posters presented at ACoP. The authors own the copyright and we recommend similar approach. Journal of Pharmacokinetics and Pharmacodynamics (JPKPD) owns the copyright to abstracts accepted at ACoP meetings prior to 2019 and are published in the JPKPD supplement.